Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImPRESS - Imaging Perfusion Restrictions from Extracellular Solid Stress
2018-003229-27Phase 2Active
- Sponsor
- Oslo University Hospital
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of losartan in glioblastoma (GBM), brain metastases and non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Oslo University Hospital. Primary endpoint: Change from baseline in relative cerebral blood flow (rCBF). Started Feb 2019; status: active.
02
Drugs
losartan
03
Conditions
glioblastoma (GBM)brain metastasesnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-003229-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003229-27.